Endurance Wealth Management Inc. lowered its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 0.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 194,856 shares of the biopharmaceutical company’s stock after selling 75 shares during the quarter. Pfizer makes up approximately 1.1% of Endurance Wealth Management Inc.’s holdings, making the stock its 29th biggest position. Endurance Wealth Management Inc.’s holdings in Pfizer were worth $6,546,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. D. Scott Neal Inc. grew its stake in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new position in shares of Pfizer during the 1st quarter valued at approximately $121,000. Cascade Investment Advisors Inc. grew its stake in shares of Pfizer by 89.1% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 2,200 shares during the period. Perennial Advisors LLC grew its stake in shares of Pfizer by 7.9% during the 2nd quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 376 shares during the period. Finally, Patten Group Inc. grew its stake in shares of Pfizer by 5.1% during the 1st quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 252 shares during the period. 69.01% of the stock is owned by hedge funds and other institutional investors.
In other news, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 389,621 shares of company stock valued at $13,298,598. Insiders own 0.06% of the company’s stock.
PFE has been the subject of a number of recent research reports. Cowen and Company set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Monday, July 10th. BidaskClub downgraded Pfizer from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 13th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Jefferies Group LLC reiterated a “hold” rating and set a $35.00 price objective (up from $34.00) on shares of Pfizer in a research note on Friday, July 14th. Finally, Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $38.35.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 EPS.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.61%. Pfizer’s dividend payout ratio is currently 79.01%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.